Guggenheim initiated coverage on shares of Eli Lilly And Co (NYSE:LLY) in a report released on Monday morning, The Fly reports. The brokerage issued a buy rating on the stock.
Other research analysts also recently issued research reports about the stock. Zacks Investment Research raised shares of Eli Lilly And Co from a hold rating to a buy rating and set a $100.00 price objective for the company in a report on Wednesday, July 18th. TheStreet raised shares of Eli Lilly And Co from a c+ rating to a b rating in a report on Friday, June 29th. Bank of America increased their price objective on shares of Eli Lilly And Co from $90.00 to $94.00 and gave the company a neutral rating in a report on Wednesday, July 25th. Cantor Fitzgerald set a $110.00 price objective on shares of Eli Lilly And Co and gave the company a buy rating in a report on Monday, September 17th. Finally, BMO Capital Markets increased their price target on shares of Eli Lilly And Co from $78.00 to $80.00 and gave the company a $89.43 rating in a report on Thursday, July 19th. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating and twelve have issued a buy rating to the stock. Eli Lilly And Co currently has an average rating of Buy and a consensus target price of $106.06.
LLY opened at $115.46 on Monday. Eli Lilly And Co has a 52 week low of $73.69 and a 52 week high of $116.61. The stock has a market cap of $115.25 billion, a price-to-earnings ratio of 26.98, a P/E/G ratio of 1.88 and a beta of 0.29. The company has a quick ratio of 1.09, a current ratio of 1.40 and a debt-to-equity ratio of 0.79.
In related news, SVP Alfonso G. Zulueta sold 7,000 shares of the stock in a transaction dated Thursday, October 4th. The shares were sold at an average price of $114.64, for a total value of $802,480.00. Following the sale, the senior vice president now directly owns 45,224 shares of the company’s stock, valued at approximately $5,184,479.36. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, major shareholder Lilly Endowment Inc sold 185,000 shares of the stock in a transaction dated Tuesday, July 24th. The stock was sold at an average price of $92.03, for a total transaction of $17,025,550.00. Following the completion of the sale, the insider now directly owns 121,631,601 shares in the company, valued at $11,193,756,240.03. The disclosure for this sale can be found here. In the last ninety days, insiders sold 1,770,943 shares of company stock valued at $178,470,135. 0.11% of the stock is owned by insiders.
A number of institutional investors have recently bought and sold shares of LLY. Susquehanna Fundamental Investments LLC purchased a new stake in Eli Lilly And Co in the 1st quarter worth about $3,093,000. A.R.T. Advisors LLC purchased a new stake in Eli Lilly And Co in the 1st quarter worth about $9,586,000. Cornercap Investment Counsel Inc. raised its position in Eli Lilly And Co by 9.2% in the 1st quarter. Cornercap Investment Counsel Inc. now owns 48,471 shares of the company’s stock worth $3,750,000 after purchasing an additional 4,085 shares during the period. The Manufacturers Life Insurance Company raised its position in Eli Lilly And Co by 1.5% in the 1st quarter. The Manufacturers Life Insurance Company now owns 1,413,180 shares of the company’s stock worth $109,337,000 after purchasing an additional 20,788 shares during the period. Finally, Ostrum Asset Management raised its position in Eli Lilly And Co by 68.1% in the 1st quarter. Ostrum Asset Management now owns 97,452 shares of the company’s stock worth $7,545,000 after purchasing an additional 39,472 shares during the period. 76.56% of the stock is currently owned by institutional investors.
Eli Lilly And Co Company Profile
Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates through two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.
Recommended Story: Fiduciary
Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.